Bellicum shares surge as FDA lifts a clinical hold on lead cell therapy following a protocol adjustment
Investors in Houston-based Bellicum $BLCM can now breathe a sigh of relief.
The company reported Wednesday evening that the FDA has lifted the clinical hold it dropped on their studies of BPX-501 after amending their trial protocols. The company did not reveal exactly what it had to do, but Bellicum performed in line with expectations in keeping the halt to a relatively brief spell.
In a newly released statement, the biotech noted:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.